24 June 2015
Mission Rabies Presents at MSD Animal Health and asks Pet Owners to Support World Rabies Day on 28th September 2014
Milton Keynes, 24th June, 2015 – Luke Gamble, Founder of Mission Rabies, presented the most recent successes of the charity’s rabies prevention programme to employees at MSD Animal Health.
The company, started its support of rabies prevention, through its Afya programme, 15 years ago, working with Sarah Cleaveland’s Afya Serengeti project. It now supports Mission Rabies in India, Malawi and Sri Lanka. The presentation marked the start of the campaign leading up to World Rabies Day on 28th September 2015. The Afya rabies prevention programme now needs the support of vets and pet owners in the UK and around the globe to help keep communities in Africa, India and Sri Lanka safe and thus help rid the world of rabies.
The Afya programme is supported by MSD Animal Health by the donation of its rabies vaccine. Each year around 59,0001 people around the world die from rabies, many of them children. Yet it is 100% preventable. Amanda Melvin, Senior Brand Manager at MSD Animal Health, responsible for the UK awareness of the programme comments: “Like Luke Gamble and the work of the Mission Rabies team, every pet owner understands the close bond we have with our dogs. When there’s a risk of rabies that relationship can become lethal for the human and dog population. That’s why we support Mission Rabies and the Afya Serengeti programmes. We want to see the end of this deadly disease but need the help of vets everywhere. The main carriers of the disease are domestic dogs and by vaccinating them we can protect both humans and animals. We have therefore expanded our support for the Afya campaign by providing rabies vaccines to rabies elimination projects in the Serengeti, India, Malawi and Sri Lanka.”
David Sutton, Global Technical Director responsible for the MSD Animal Health small animal vaccines: “Controlling rabies is vital to the health of the whole community. By vaccinating dogs in developing nations we help protect the human, domestic dog and wildlife populations. We believe that every community should be free of rabies. It’s a goal worth aspiring to.”
Sutton continues: “World Rabies Day that takes place each year on the 28th of September and is a great opportunity for everybody to get involved and show support for people living in communities affected by the disease. Your community may be free of rabies but not everyone’s is, yet. You can help change this. To participate all you need to do is go to the Afya website: www.afya.org.”
For further information go to: www.afya.org, www.missionrabies.com, http://rabiesalliance.org/world-rabies-day/
1 Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. (2015) Estimating the Global Burden of Endemic Canine Rabies. PLoS Negl Trop Dis 9(4): e0003709. doi:10.1371/journal. pntd.0003709
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These 3 statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).